scholarly journals The history of coronary surgery development

2021 ◽  
pp. 15-25
Author(s):  
A.G. Muradov ◽  
◽  
V.U. Efendiev ◽  
A.V. Andin ◽  
D.B. Drobot ◽  
...  
Keyword(s):  
Heart Disease ◽  
Ischaemic Heart Disease ◽  
Coronary Bypass ◽  
Bypass Grafting ◽  
Coronary Surgery ◽  
Coronary Bypass Grafting ◽  
Advantages And Disadvantages ◽  
History Of ◽  
In The Beginning ◽  
Direct Bypass

The leading place among cardiovascular diseases in the world – 50% – belongs to the ischaemic heart disease. Coronary bypass grafting is the golden standard for treatment of patients with multivessel ischaemic heart disease. The modern level of coronary surgery makes it possible to perform safe and efficacious direct revascularisation with hospital lethality not exceeding 1-3%. This article presents a review of literature devoted to the history of coronary surgery development including analysis of relevant sources dated 2010-2020 published in PubMed and Google Scholar databases: from first experimental procedures in the beginning of the 20th century and indirect myocardial revascularisation methods to direct bypass grafting of the impaired heart vessels actively developed since early 1960s. The article describes types of grafts applied with description of advantages and disadvantages of each one as well as contemporary methods and conditions for coronary bypass grafting and further prospects in development of ischaemic heart disease surgery.

The secondary prevention for ischaemic heart disease after coronary bypass grafting – follow up study

2017 ◽  
Vol 263 ◽  
pp. e158
Author(s):  
Vera Adamkova ◽  
Petr Kacer ◽  
Jaroslav Hubacek ◽  
Ivana Kralova Lesna ◽  
Vera Lanska ◽  
...  
Keyword(s):  
Heart Disease ◽  
Secondary Prevention ◽  
Ischaemic Heart Disease ◽  
Coronary Bypass ◽  
Bypass Grafting ◽  
Coronary Bypass Grafting ◽  
Follow Up Study

History of Surgical Treatment of Ischemic Heart Disease?Pre-?Coronary Bypass Grafting? Era

2007 ◽  
Vol 22 (3) ◽  
pp. 242-246 ◽  
Author(s):  
Pawan Kumar ◽  
Fuad Moussa ◽  
Nachum Nesher ◽  
Bernard Goldman
Keyword(s):  
Heart Disease ◽  
Surgical Treatment ◽  
Ischemic Heart Disease ◽  
Coronary Bypass ◽  
Ischemic Heart ◽  
Bypass Grafting ◽  
Coronary Bypass Grafting ◽  
History Of

scholarly journals CARDIAC-ANKLE VESSEL INDEX AND SHORT TERM RESULTS OF CORONARY BYPASS GRAFTING IN CORONARY HEART DISEASE

2015 ◽  
pp. 78-84 ◽  
Author(s):  
A. N. Sumin ◽  
A. V. Shcheglova ◽  
A. V. Osokina ◽  
N. V. Fedorova ◽  
E. A. Zhuchkova ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Coronary Bypass ◽  
Bypass Grafting ◽  
Short Term ◽  
Coronary Bypass Grafting

scholarly journals PPARG2 Pro12Ala and TNFα -308G>A Polymorphisms Are Not Associated with Heart Failure Development in Patients with Ischemic Heart Disease after Coronary Artery Bypass Grafting

PPAR Research ◽  
2019 ◽  
Vol 2019 ◽  
pp. 1-7
Author(s):  
Izabela Wojtkowska ◽  
Tomasz A. Bonda ◽  
Andrzej Tysarowski ◽  
Katarzyna Seliga ◽  
Janusz A. Siedlecki ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coronary Artery Disease ◽  
Heart Disease ◽  
Coronary Artery ◽  
Ischemic Heart Disease ◽  
Coronary Bypass ◽  
Ischemic Heart ◽  
Bypass Grafting ◽  
Coronary Bypass Grafting ◽  
Artery Disease

TNFα and PPARγ are important modulators of metabolism, inflammation, and atherosclerosis. Coronary artery disease is the leading cause of heart failure (HF). The aim of the study was to assess whether polymorphisms of the TNFα (-308G>A) and PPARG2 (Pro12Ala) genes are associated with the risk of developing HF by patients with ischemic heart disease. Methods. 122 patients without HF (aged 63 ± 8.8 years, 85% males) with confirmed coronary artery disease qualified for coronary bypass grafting were enrolled in the study. After the procedure, they were screened for cardiac parameters. Those with elevated NT-proBNP or diminished left ventricular ejection fraction during follow-up were assigned to the HF group (n=78), and the remaining ones to the non-HF group (n=44). The TNFα -308G>A and PPARG2 Pro12Ala polymorphisms were detected using the TaqMan method. Results. The distributions of TNFα -308G>A and PPARG2 Pro12Ala did not differ between the HF and non-HF groups (-308G>A: 16% vs. 11.4% of alleles; Pro12Ala: 23.9% vs. 20.5% of alleles, respectively). IL-6 concentration in the plasma of TNFα A-allele carriers at months 1 and 12 after CABG was higher in the HF group compared to the non-HF group (1 month after CABG: 5.3 ± 3.4 vs. 3.1 ± 2.9, p<0.05; 12 months after CABG: 4.2 ± 3,9 vs. 1.4 ± 1.2, p<0.01, respectively). Both polymorphisms were not related to changes in the plasma TNFα concentration or other parameters related to HF. Conclusions. Our study did not reveal any correlation between the PPARG2 Pro12Ala and TNFα -308G>A polymorphisms and development of HF in patients with ischemic heart disease after coronary bypass grafting.

DOES HISTORY OF PERCUTANEOUS INTERVENTION IMPACT OUTCOMES FOLLOWING A SUBSEQUENT CORONARY BYPASS GRAFTING SURGERY?

CHEST Journal ◽  
2008 ◽  
Vol 134 (4) ◽  
pp. 2P
Author(s):  
Henry A. Tran ◽  
Scott D. Barnett ◽  
Sharon L. Hunt ◽  
Niv Ad
Keyword(s):  
Coronary Bypass ◽  
Percutaneous Intervention ◽  
Bypass Grafting ◽  
Coronary Bypass Grafting ◽  
Intervention Impact ◽  
History Of

Diltiazem versus Amiodarone to Prevent Atrial Fibrillation in Coronary Surgery

2005 ◽  
Vol 13 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Dimitrios Mikroulis ◽  
Vassilios Didilis ◽  
Fotios Konstantinou ◽  
Kosmas Tsakiridis ◽  
Georgios Vretzakis ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Beta Blocker ◽  
Coronary Bypass ◽  
Control Group ◽  
Bypass Grafting ◽  
Prophylactic Effect ◽  
Coronary Surgery ◽  
Prophylactic Regimen ◽  
Coronary Bypass Grafting ◽  
Prophylactic Use

The prophylactic effect of amiodarone on atrial fibrillation after coronary bypass grafting with extracorporeal circulation was compared with that of diltiazem in two groups of 60 patients each. Patients were monitored continuously for 8 days. The incidence of atrial fibrillation was recorded retrospectively in a control group of 60 patients who received our standard prophylactic regimen of an oral beta blocker. The incidence of postoperative atrial fibrillation was not significantly different in the two test groups: 11.7% for the amiodarone group and 10% for the diltiazem group. The incidence of atrial fibrillation in the control group was 23.3% and the differences were marginally significant when compared to the amiodarone ( p = 0.093) and diltiazem groups ( p = 0.050). The prophylactic use of diltiazem or amiodarone is feasible and safe for patients undergoing coronary bypass, with similar rates of atrial fibrillation.

scholarly journals DISORDERS OF RESPIRATORY FUNCTION OF LUNGS IN PATIENTS WITH ISCHEMIC HEART DISEASE BEFORE PLANNING CORONARY BYPASS GRAFTING

2017 ◽  
pp. 77-84
Author(s):  
E.D. Bazdyrev ◽  
O.M. Polikutina ◽  
N.A. Kalichenko ◽  
Yu.S. Slepynina ◽  
O.L. Barbarash
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Respiratory Function ◽  
Coronary Bypass ◽  
Ischemic Heart ◽  
Bypass Grafting ◽  
Coronary Bypass Grafting
Sign in / Sign up

Export Citation Format

Share Document